Clinical Trial Update: Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imlunestrant in combination with abemaciclib for estrogen receptor-positive breast cancer with minimal residual disease; current status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Invasive Breast Carcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)
• Imlunestrant (imlunestrant)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Status: NOT_YET_RECRUITING